

Kompletní seznam literatury k práci: Fedorko Michal, Bohošová Júlia, Poprach Alexandr, Pacík Dalibor. Dlouhé nekódující RNA a karcinom z renálních buněk. Klin Onkol 2020, 33(5), 340-349. DOI: 10.14735/amko2020340.

1. Miller KD, Nogueira L, Mariotto AB et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin* 2019; 69(5): 363–385. doi: 10.3322/caac.21565.
2. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Dostupné z: <http://www.svod.cz>.
3. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975–2016. [online]. Dostupné z: http://seer.cancer.gov/csr/1975_2016.
4. Yang L, Froberg JE, Lee JT. Long noncoding RNAs: fresh perspectives into the RNA world. *Trends Biochem Sci* 2014; 39(1): 35–43. doi: 10.1016/j.tibs.2013.10.002.
5. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. *Cancer Cell* 2016; 29(4): 452–463. doi: 10.1016/j.ccell.2016.03.010.
6. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. *RNA Biol* 2012; 9(6): 703–719. doi: 10.4161/rna.20481.
7. Zhou H, Guo L, Yao WM et al. Silencing of tumor-suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency. *J Cell Physiol* 2019. [in press]. doi: 10.1002/jcp.29115.
8. Song EL, Xing L, Wang L et al. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis. *Aging* 2019; 11(15): 5705–5725. doi: 10.18632/aging.102154.
9. Luo NQ, Ma DR, Yang XC et al. Long non-coding RNA ENST00000434223 inhibits the progression of renal cancer through Wnt/hygro-catenin signaling pathway. *Eur Rev Med Pharmacol Sci* 2019; 23(16): 6868–6877. doi: 10.26355/eurev_201908_18726.
10. Gao ZZ, Chen MJ, Tian XK et al. A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma. *RNA Biol* 2019; 16(7): 940–949. doi: 10.1080/15476286.2019.1602436.
11. Dong JP, Zheng SP, Yang XY et al. Cell proliferation in kidney carcinoma is inhibited by lncRNA GASL1. *Eur J Inflamm* 2019; 17: 1–6. doi: 10.1177/2058739219854598.
12. Chen DM, Zhu M, Su H et al. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma. *J Cell Physiol* 2019; 234(5): 725–765. doi: 10.1002/jcp.27483.
13. Sun K, Jia ZK, Duan RR et al. Long non-coding RNA XIST regulates miR-106b-5p/P21 axis to suppress tumor progression in renal cell carcinoma. *Biochem Biophys Res Commun* 2019; 510(3): 416–420. doi: 10.1016/j.bbrc.2019.01.116.
14. Wang G, Zhang ZJ, Jian WG et al. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/beta-catenin signaling pathway. *Mol Cancer* 2019; 18: 1–15. doi: 10.1186/s12943-019-0942-1.
15. Yang F, Wu QJ, Zhang L et al. The long noncoding RNA KCNQ1DN suppresses the survival of renal cell carcinoma cells through downregulating c-Myc. *J Cancer* 2019; 10(19): 4662–4670. doi: 10.7150/jca.29280.
16. He HC, Dai J, Zhuo R et al. Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling. *J Cell Physiol* 2018; 233(12): 9503–9515. doi: 10.1002/jcp.26849.
17. Wang M, Huang T, Luo G et al. Long non-coding RNA MEG3 induces renal cell carcinoma cells apoptosis by activating the mitochondrial pathway. *J Huazhong Univ Sci Technol Med Sci* 2015; 35(4): 541–545. doi: 10.1007/s11596-015-1467-5.

18. Wang CL, Wang G, Zhang ZJ et al. The downregulated long noncoding RNA DHRS4-AS1 is protumoral and associated with the prognosis of clear cell renal cell carcinoma. *Onco Targets Ther* 2018; 11: 5631–5646. doi: 10.2147/OTT.S164984.
19. Jin L, Quan J, Pan X et al. Identification of lncRNA EGOT as a tumor suppressor in renal cell carcinoma. *Mol Med Rep* 2017; 16(5): 7072–7079. doi: 10.3892/mmr.2017.7470.
20. Jin L, Fu HF, Quan J et al. Overexpression of long non-coding RNA differentiation antagonizing non-protein coding RNA inhibits the proliferation, migration and invasion and promotes apoptosis of renal cell carcinoma. *Mol Med Rep* 2017; 16(4): 4463–4468. doi: 10.3892/mmr.2017.7135.
21. Zhai W, Sun Y, Guo CC et al. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miRNA-143-3p signals. *Cell Death and Differ* 2017; 24(9): 1502–1517. doi: 10.1038/cdd.2017.74.
22. Zhai W, Chang C, Zheng JH et al. LncRNA-SARCC suppresses clear cell renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miRNA-143-3p signals. *Cell Death Differ* 2017; 24(9): 1502–1517. doi: 10.1038/cdd.2017.74.
23. Zhai W, Sun Y, Jiang M et al. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2 alpha/C-MYC axis under hypoxia. *Oncogene* 2016; 35(37): 4866–4880. doi: 10.1038/onc.2016.19.
24. Liu YY, Qian J, Li X et al. Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibition of TGF-beta 1/p38/HSP27 signaling in renal cell carcinoma. *Oncotarget* 2016; 7(49): 81410–81422. doi: 10.18632/oncotarget.12937.
25. Cao YJ, Xu RF, Xu XL et al. Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. *Mol Med Rep* 2016; 14(1): 1019–1025. doi: 10.3892/mmr.2016.5337.
26. Liu Z, Yan HY, Xia SY et al. Downregulation of long non-coding RNA TRIM52-AS1 functions as a tumor suppressor in renal cell carcinoma. *Mol Med Rep* 2016; 13(4): 3206–3212. doi: 10.3892/mmr.2016.4908.
27. Wang ZQ, Liu Q, Li TQ et al. Abnormal expressed long non-coding RNA IRAIN inhibits tumor progression in human renal cell carcinoma cells. *Open Life Sci* 2016; 11(1): 200–205. doi: 10.1515/biol-2016-0026.
28. Qiao HP, Gao WS, Huo JX et al. Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. *Asian Pac J Cancer Prev* 2013; 14(2): 1077–1082. doi: 10.7314/apjcp.2013.14.2.1077.
29. Song C, Xiong YH, Liao WB et al. Long noncoding RNA ATB participates in the development of renal cell carcinoma by downregulating p53 via binding to DNMT1. *J Cell Physiol* 2019; 234(8): 12910–12917. doi: 10.1002/jcp.27957.
30. Xiong J, Liu Y, Jiang L et al. High expression of long non-coding RNA lncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma. *Jpn J Clin Oncol* 2016; 46(4): 378–384. doi: 10.1093/jjco/hyv214.
31. Zhang HM, Li W, Gu WY et al. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5. *Cell Prolif* 2019; 52(5): e12640. doi: 10.1111/cpr.12640.
32. Kulkarni P, Dasgupta P, Bhat NS et al. Elevated miR-182-5p associates with renal cancer cell mitotic arrest through diminished MALAT-1 expression. *Mol Cancer Res* 2018; 16(11): 1750–1760. doi: 10.1158/1541-7786.MCR-17-0762.
33. Jiang LT, Wan CH, Guo QH et al. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes renal cell carcinoma progression via sponging miRNA-429. *Med Sci Monit* 2018; 24:1794–1801. doi: 10.12659/MSM.909450.

34. Chen SA, Ma PP, Zhao Y et al. Biological function and mechanism of MALAT-1 in renal cell carcinoma proliferation and apoptosis: role of the MALAT-1-Livin protein interaction. *J Physiol Sci* 2017; 67(5): 577–585. doi: 10.1007/s12576-016-0486-8.
35. Hirata H, Hinoda Y, Shahryari V et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. *Cancer Res* 2015; 75(7): 1322–1331. doi: 10.1158/0008-5472.CAN-14-2931.
36. Zhai W, Zhu R, Ma J et al. A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. *Mol Cancer* 2019; 18(1): 81. doi: 10.1186/s12943-019-0998-y.
37. Zheng XL, Zhang YY, Lv WG. Long noncoding RNA ITGB1 promotes migration and invasion of clear cell renal cell carcinoma by downregulating Mcl-1. *Eur Rev Med Pharmacol Sci* 2019; 23(5): 1996–2002. doi: 10.26355/eurrev_201903_17238.
38. Xie WJ, Chen Q, Liu X et al. Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. *Oncol Lett* 2019; 17(3): 3173–3180. doi: 10.3892/ol.2019.9967.
39. Su Y, Lu JX, Chen XG et al. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway. *J Cancer Res Clin Oncol* 2019; 145(3): 573–588. doi: 10.1007/s00432-018-2808-0.
40. Wang QF, Wu GZ, Zhang ZW et al. Long non-coding RNA HOTTIP promotes renal cell carcinoma progression through the regulation of the miR-615/IGF-2 pathway. *Int J Oncol* 2018; 53(5): 2278–2288. doi: 10.3892/ijo.2018.4539.
41. Peng FF, Shi XL, Meng Y et al. Long non-coding RNA HOTTIP is upregulated in renal cell carcinoma and regulates cell growth and apoptosis by epigenetically silencing of LATS2. *Biomed Pharmacother* 2018; 105: 1133–1140. doi: 10.1016/j.biopha.2018.06.081.
42. Pan Y, Wu YJ, Hu JL et al. Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha-2,8-sialyltransferase 4 by sponging microRNA-124. *Cell Prolif* 2018; 51(6): e12507. doi: 10.1111/cpr.12507.
43. Ding J, Yeh CR, Sun Y et al. Estrogen receptor beta promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. *Oncogene* 2018; 37(37): 5037–5053. doi: 10.1038/s41388-018-0175-6.
44. Hong Q, Li O, Zheng W et al. LncRNA HOTAIR regulates HIF-1 alpha/AXL signaling through inhibition of miR-217 in renal cell carcinoma. *Cell Death Dis* 2017; 8: e2772. doi: 10.1038/cddis.2017.181.
45. Dong D, Mu ZY, Wei N et al. Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway. *Biomed Pharmacother* 2019; 111: 917–925. doi: 10.1016/j.biopha.2018.12.143.
46. Wang AB, Bao Y, Wu ZJ et al. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer. *Cell Death Dis* 2019; 10: 154. doi: 10.1038/s41419-019-1331-9.
47. Duan JY, Ma X, Shi J et al. Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. *Onco Targets Ther* 2019; 12: 4729–4740. doi: 10.2147/OTT.S202938.
48. Mu ZY, Dong D, Wei N et al. Silencing of lncRNA AFAP1-AS1 inhibits cell growth and metastasis in clear cell renal cell carcinoma. *Oncol Res* 2019; 27(6): 653–661. doi: 10.3727/096504018X15420748671075.
49. Ren Y, Huang WP, Weng GB et al. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p. *Onco Targets Ther* 2019; 12: 2563–2575. doi: 10.2147/OTT.S190239.

50. Li WC, Zheng ZS, Chen HC et al. Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. *Oncol Lett* 2018; 15(5): 7855–7863. doi: 10.3892/ol.2018.8315.
51. Wu QJ, Yang F, Yang ZX et al. Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1. *Oncotarget* 2017; 8(60): 101865–101875. doi: 10.18632/oncotarget.21706.
52. Yang T, Zhou H, Liu PJ et al. lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. *Oncotarget* 2017; 8(49): 85353–85367. doi: 10.18632/oncotarget.19743.
53. Liu S, Yang YT, Wang WW et al. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP. *J Cell Biochem* 2018; 119(12): 9694–9706. doi: 10.1002/jcb.27284.
54. Yang Y, Sun DM, Yu JF et al. Long noncoding RNA TUG1 promotes renal cell carcinoma cell proliferation, migration and invasion by downregulating microRNA-196a. *Mol Med Rep* 2018; 18(6): 5791–5798. doi: 10.3892/mmr.2018.9608.
55. Ding CG, Han F, Xiang HL et al. LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma. *J Cell Biochem* 2018; 119(12): 10406–10414. doi: 10.1002/jcb.27389.
56. Shao K, Shi TM, Yang Y et al. Highly expressed lncRNA CRNDE promotes cell proliferation through Wnt/beta-catenin signaling in renal cell carcinoma. *Tumor Biol* 2016; 37(12): 15997–16004. doi: 10.1007/s13277-016-5440-0.
57. Yang FQ, Zhang JQ, Jin JJ et al. HOXA11-AS promotes the growth and invasion of renal cancer by sponging miR-146b-5p to upregulate MMP16 expression. *J Cell Physiol* 2018; 233(12): 961–969. doi: 10.1002/jcp.26864.
58. Huang T, Wang X, Yang XK et al. Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126. *Med Sci Monit* 2018; 24: 7340–7347. doi: 10.12659/MSM.910054.
59. Wang LN, Zhu XQ, Song XS et al. Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR-495-3p. *J Cell Biochem* 2018; 119(9): 7599–7609. doi: 10.1002/jcb.27099.
60. Zheng ZS, Zhao FJ, Zhu DJ et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3 beta signaling pathway. *Cell Physiol Biochem* 2018; 48(3): 891–904. doi: 10.1159/000491957.
61. Xiao HB, Bao L, Xiao W et al. Long non-coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma. *Oncotarget* 2017; 8(69): 113622–113634. doi: 10.18632/oncotarget.21185.
62. Liu GH, Ye ZX, Zhao X et al. SP1-induced up-regulation of lncRNA SNHG14 as a ceRNA promotes migration and invasion of clear cell renal cell carcinoma by regulating N-WASP. *Am J Cancer Res* 2017; 7(12): 2515–2525.
63. Du Y, Kong CZ, Zhu YY et al. Knockdown of SNHG15 suppresses renal cell carcinoma proliferation and EMT by regulating the NF- κ B signaling pathway. *Int J Oncol* 2018; 53(1): 384–394. doi: 10.3892/ijo.2018.4395.
64. Ye XT, Huang H, Huang WP et al. LncRNA THOR promotes human renal cell carcinoma cell growth. *Biochem Biophys Res Commun* 2018; 501(3): 661–667. doi: 10.1016/j.bbrc.2018.05.040.
65. Zhao SY, Wang YW, Luo MY et al. Long noncoding RNA small nucleolar RNA host gene 1 (SNHG1) promotes renal cell carcinoma progression and metastasis by negatively regulating miR-137. *Med Sci Monit* 2018; 24: 3824–3831. doi: 10.12659/MSM.910866.

66. Qu Y, Xiao HB, Xiao W et al. Upregulation of MIAT regulates LOXL2 expression by competitively binding MiR-29c in clear cell renal cell carcinoma. *Cell Physiol Biochem* 2018; 48(3): 1075–1087. doi: 10.1159/000491974.
67. Liu GH, Zhao X, Zhou JM et al. LncRNA TP73-AS1 promotes cell proliferation and inhibits cell apoptosis in clear cell renal cell carcinoma through repressing KISS1 expression and inactivation of PI3K/Akt/mTOR signaling pathway. *Cell Physiol Biochem* 2018; 48(1): 371–384. doi: 10.1159/000491767.
68. Zhang WH, Wang J, Chai R et al. Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas. *Onco Targets Ther* 2018; 11: 4537–4545. doi: 10.2147/OTT.S169155.
69. Liu Q, Li Y, Lv WL et al. UCA1 promotes cell proliferation and invasion and inhibits apoptosis through regulation of the miR129-SOX4 pathway in renal cell carcinoma. *Onco Targets Ther* 2018; 11: 2475–2487. doi: 10.2147/OTT.S160192.
70. Lu Y, Liu WG, Lu JH et al. LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. *Tumor Biol* 2017; 39(5). doi: 10.1177/1010428317701632.
71. Li YF, Wang TT, Li YC et al. Identification of long-non coding RNA UCA1 as an oncogene in renal cell carcinoma. *Mol Med Rep* 2016; 13(4): 3326–3334. doi: 10.3892/mmr.2016.4894.
72. He ZH, Qin XH, Zhang XL et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma. *Eur Rev Med Pharmacol Sci* 2018; 22(1): 46–54. doi: 10.26355/eurrev_201801_14099.
73. He HW, Wang NN, Yi XM et al. Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. *Cell Biosci* 2017; 7: 65. doi: 10.1186/s13578-017-0193-z.
74. Shi JG, Zhang W, Tian HY et al. LncRNA ROR promotes the proliferation of renal cancer and is negatively associated with favorable prognosis. *Mol Med Rep* 2017; 16(6): 9561–9565. doi: 10.3892/mmr.2017.7775.
75. Wang KF, Jin W, Song Y et al. LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma. *Mol Cancer* 2017; 16(1): 166. doi: 10.1186/s12943-017-0735-3.
76. He XF, Liu HJ, Guo FF et al. Long non-coding RNA Z38 promotes cell proliferation and metastasis in human renal cell carcinoma. *Mol Med Rep* 2017; 16(4): 5489–5494. doi: 10.3892/mmr.2017.7218.
77. Chen SA, Ma PP, Li B et al. LncRNA CCAT1 inhibits cell apoptosis of renal cell carcinoma through up-regulation of Livin protein. *Mol Cell Biochem* 2017; 434(1–2): 135–142. doi: 10.1007/s11010-017-3043-8.
78. Liu F, Chen N, Gong YC et al. The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma. *Oncotarget* 2017; 8(38): 62927–62938. doi: 10.18632/oncotarget.17757.
79. Ning L, Li ZG, Wei DJ et al. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma. *Cancer Biomark* 2017; 19(1): 75–83. doi: 10.3233/CBM-160376.
80. Li JK, Chen C, Liu JY et al. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling. *Mol Cancer* 2017; 16(1): 111. doi: 10.1186/s12943-017-0681-0.
81. Xu Z, Yang F, Wei D et al. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. *Oncogene* 2017; 36(14): 1965–1977. doi: 10.1038/onc.2016.356.

82. Xiong J, Liu Y, Luo SJ et al. High expression of the long non-coding RNA HEIRCC promotes renal cell carcinoma metastasis by inducing epithelial-mesenchymal transition. *Oncotarget* 2017; 8(4): 6555–6563. doi: 10.18632/oncotarget.14149.
83. Li QC, Tian Y, Hu GR et al. Highly expressed antisense noncoding RNA in the INK4 locus promotes growth and invasion of renal clear carcinoma cells via the beta-catenin pathway. *Oncol Res* 2017; 25(8): 1373–1382. doi: 10.3727/096504017X14878509668646.
84. Zhang JL, Cao ZJ, Ding X et al. The lncRNA XIST regulates the tumorigenicity of renal cell carcinoma cells via the miR-302c/SDC1 axis. *Int J Clin Exp Pathol* 2017; 10(7): 7481–7491.
85. Wang YJ, Liu JZ, Bai HZ et al. Long intergenic non-coding RNA 00152 promotes renal cell carcinoma progression by epigenetically suppressing P16 and negatively regulates miR-205. *Am J Cancer Res* 2017; 7(2): 312–322.
86. Ren XF, Lan TB, Chen Y et al. LncRNA uc009yby.1 promotes renal cell proliferation and is associated with poor survival in patients with clear cell renal cell carcinomas. *Oncol Lett* 2016; 12(3): 1929–1934. doi: 10.3892/ol.2016.4856.
87. Qu L, Ding J, Chen C et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. *Cancer Cell* 2016; 29(5): 653–668. doi: 10.1016/j.ccell.2016.03.004.
88. Bertozzi D, Iurlaro R, Sordet O et al. Characterization of novel antisense HIF-1 alpha transcripts in human cancers. *Cell Cycle* 2011; 10(18): 3189–3197. doi: 10.4161/cc.10.18.17183.
89. Yu G, Yao WM, Wang J et al. LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. *Plos One* 2012; 7(8): e42377. doi: 10.1371/journal.pone.0042377.
90. Fachel AA, Tahira AC, Vilella-Arias SA et al. Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: emerging functional associations. *Mol Cancer* 2013; 12(1): 140. doi: 10.1186/1476-4598-12-140.
91. Malouf GG, Zhang JP, Yuan Y et al. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. *Mol Oncol* 2015; 9(1): 32–43. doi: 10.1016/j.molonc.2014.07.007.
92. Blondeau JJ, Deng M, Syring I et al. Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. *Clin Epigenetics* 2015; 7(1): 10. doi: 10.1186/s13148-015-0047-7.
93. Deng M, Blondeau JJ, Schmidt D et al. Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. *Genom Data* 2015; 5: 173–175. doi: 10.1016/j.gdata.2015.06.016.
94. He HT, Xu M, Kuang Y et al. Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma. *Onco Targets Ther* 2016; 9: 6399–6406. doi: 10.2147/OTT.S116392.
95. Xu X, Xu YC, Shi CQ et al. A genome-wide comprehensively analyses of long noncoding RNA profiling and metastasis associated lncRNAs in renal cell carcinoma. *Oncotarget* 2017; 8(50): 87773–87781. doi: 10.18632/oncotarget.21206.
96. Yin H, Wang XY, Zhang X et al. Integrated analysis of long noncoding RNA associated-competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma. *Cancer Sci* 2018; 109(10): 3336–3349. doi: 10.1111/cas.13778.
97. Ellinger J, Alam J, Rothenburg J et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. *Am J Cancer Res* 2015; 5(9): 2799–2807.
98. Fedorko M, Kubíčková A, Kováčová J et al. Dlouhé nekódující RNA jako diagnostické biomarkery renálního karcinomu. *Ces Urol* 2019; 23 (Suppl. A): 64.

99. Jiang N, Pan J, Fang S et al. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer. *Clin Chim Acta* 2019; 495: 331–337. doi: 10.1016/j.cca.2019.04.082.
100. Wu Y, Wang YQ, Weng WW et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. *Oncogenesis* 2016; 5: e192. doi: 10.1038/oncsis.2015.48.
101. Kohls K, Schmidt D, Holdenrieder S et al. Detection of cell-free lncRNA in serum of cancer patients. *Urologe A* 2015; 54(6): 819–825. doi: 10.1007/s00120-014-3655-5.
102. Zeng JH, Lu W, Liang L et al. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data. *J Transl Med* 2019; 17(1): 281. doi: 10.1186/s12967-019-2032-y.
103. Jiang W, Guo Q, Wang CH et al. A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma. *Cancer Cell Int* 2019; 19(1): 208. doi: 10.1186/s12935-019-0928-5.
104. Zuo SG, Wang LP, Wen YQ et al. Identification of a universal 6-lncRNA prognostic signature for three pathologic subtypes of renal cell carcinoma. *J Cell Biochem* 2019; 120(5): 7375–7385. doi: 10.1002/jcb.28012.
105. Wang JW, Zhang CY, He WY et al. Construction and comprehensive analysis of dysregulated long non-coding RNA-associated competing endogenous RNA network in clear cell renal cell carcinoma. *J Cell Biochem* 2019; 120(2): 2576–2593. doi: 10.1002/jcb.27557.
106. Qu L, Wang ZL, Chen Q et al. Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma. *Eur Urol* 2018; 74(6): 756–763. doi: 10.1016/j.eururo.2018.07.032.
107. Chen BH, Wang CY, Zhang J et al. New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma. *Cancer Cell Int* 2018; 18: 157. doi: 10.1186/s12935-018-0652-6.
108. Liu T, Sui J, Zhang Y et al. Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma. *Oncol Rep* 2018; 40(3): 1503–1514. doi: 10.3892/or.2018.6540.
109. Gao HW, Chen XR, Shang ZQ et al. Prognostic signatures for renal cancer as identified by long non-coding and miRNA competing endogenous network analysis. *Oncol Rep* 2018; 40(2): 959–967. doi: 10.3892/or.2018.6476.
110. Su HC, Wang HK, Shi GH et al. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. *Eur J Surg Oncol* 2018; 44(6): 840–846. doi: 10.1016/j.ejso.2018.01.013.
111. Yang K, Lu XF, Luo PC et al. Identification of six potentially long noncoding RNAs as biomarkers involved competitive endogenous RNA in clear cell renal cell carcinoma. *Biomed Res Int* 2018; 9303486: 1–13. doi: 10.1155/2018/9303486.
112. Lan HH, Zeng JH, Chen G et al. Survival prediction of kidney renal papillary cell carcinoma by comprehensive lncRNA characterization. *Oncotarget* 2017; 8(67): 110811–110829. doi: 10.18632/oncotarget.22732.
113. Yang FY, Wang Y, Wu JG et al. Analysis of long non-coding RNA expression profiles in clear cell renal cell carcinoma. *Oncol Lett* 2017; 14(3): 2757–2764. doi: 10.3892/ol.2017.6563.
114. Shi D, Qu QH, Chang QM et al. A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. *Oncotarget* 2017; 8(35): 58699–58708. doi: 10.18632/oncotarget.17506.
115. Jin P, Wang J, Liu Y. Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. *Exp Ther Med* 2017; 13(3): 1137–1142. doi: 10.3892/etm.2017.4080.

116. Su HC, Sun TT, Wang HK et al. Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. *Oncotarget* 2017; 8(4): 5789–5799. doi: 10.18632/oncotarget.11011.
117. Ni WJ, Song EL, Gong MC et al. Downregulation of lncRNA SDPR-AS is associated with poor prognosis in renal cell carcinoma. *Onco Targets Ther* 2017; 10: 3039–3047. doi: 10.2147/OTT.S137641.
118. Xue S, Li QW, Che JP et al. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. *Int J Clin Exp Pathol* 2015; 8(4): 3765–3774.
119. Bao X, Duan JY, Yan YJ et al. Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. *Cancer Biomark* 2018; 21(1): 55–63. doi: 10.3233/CBM-170251.
120. An HX, Xu B, Wang Q et al. Up-regulation of long non-coding RNA SNHG6 predicts poor prognosis in renal cell carcinoma. *Eur Rev Med Pharmacol Sci* 2018; 22(24): 8624–8629. doi: 10.26355/eurrev_201812_16626.
121. Flippot R, Mouawad R, Spano JP et al. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. *Sci Rep* 2017; 7(1): 8540. doi: 10.1038/s41598-017-08363-6.
122. Qi JJ, Liu YX, Lin L. High expression of long non-coding RNA ATB is associated with poor prognosis in patients with renal cell carcinoma. *Eur Rev Med Pharmacol Sci* 2017; 21(12): 2835–2839.
123. Xu Y, Tong YY, Zhu JY et al. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma. *BMC Cancer* 2017; 17(1): 373. doi: 10.1186/s12885-017-3339-9.
124. Gong X, Siprashvili Z, Eminaga O et al. Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. *Oncotarget* 2017; 8(12): 18657–18669. doi: 10.18632/oncotarget.15703.
125. Wang PQ, Wu YX, Zhong XD et al. Prognostic significance of overexpressed long non-coding RNA TUG1 in patients with clear cell renal cell carcinoma. *Eur Rev Med Pharmacol Sci* 2017; 21(1): 82–86.
126. Wu Y, Tan C, Weng WW et al. Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma. *Am J Cancer Res* 2016; 6(2): 285–299.
127. Zhang HM, Yang FQ, Chen SJ et al. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. *Tumor Biol* 2015; 36(4): 2947–2955. doi: 10.1007/s13277-014-2925-6.
128. Wang L, Cai Y, Zhao X et al. Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma. *Neoplasma* 2015; 62(3): 412–418. doi: 10.4149/neo_2015_049.
129. Yao J, Chen Y, Wang YC et al. Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas. *Int J Clin Exp Pathol* 2014; 7(6): 2758–2767.
130. Zhang HM, Yang FQ, Yan Y et al. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. *Int J Clin Exp Pathol* 2014; 7(9): 5801–5809.
131. Xing QW, Li R, Xu AM et al. Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma. *Cancer Med* 2019; 8(6): 2886–2896. doi: 10.1002/cam4.2160.

132. Chen D, Zhu M, Su H et al. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma. *J Cell Physiol* 2019; 234(5): 7257–7265. doi: 10.1002/jcp.27483.
133. He XF, Sun FG, Guo FF et al. Knockdown of long noncoding RNA FTX inhibits proliferation, migration, and invasion in renal cell carcinoma cells. *Oncol Res* 2017; 25(2): 157–166. doi: 10.3727/096504016X14719078133203.